Renewable Energy

VBI hepatitis B vaccine meets main goals in late-stage trial

VBI Vaccines Inc said on Monday a late-stage study testing its hepatitis B vaccine met its main goals.

June 17 (Reuters) - VBI Vaccines Inc VBIV.O said on Monday a late-stage study testing its hepatitis B vaccine met its main goals.

The trial tested VBI's Sci-B-Vac against GlaxoSmithKline's GSK.L's Engerix-B vaccine, which was first approved in the United States in 1989.

(Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh Kuber)

((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 1208; Reuters Messaging: tamara.mathias.thomsonreuters.com@reuters.net))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More